Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: AuBug who wrote (187)	8/10/2003 2:38:45 PM
From: Hank	Read Replies (2) \| Respond to of 684

Thanks for the concise explanation. After you mentioned it the last time, I asked around to find out why some large pharmaceutical companies were reluctant to use this approach versus the hybrid mouse. The answer was, "Because nobody has been able to develop an antibody therapy yet using phage display." I can't say if this is true or not but the answer was not surprising. Big drug companies tend to be very superstitious about these things and will only invest the time and money if somebody has already used the approach to bring a drug to market.